Abstract
Pneumonia is an infection on the lung tissue that caused the lung would not be able to work properly. The first-line choice of therapy in pneumonia is using cephalosporin class of antibiotic which are ceftriaxone and cefotaxime. Both of those therapies have significant difference in cost, so that a pharmaceconomic analysis needs to be done using the cost-minimization analysis (CMA) method. This research to analyze minimization cost of antibiotic ceftriaxone and cefotaxime in adult pneumonia patients with cured outcomes in inpatients at RSUD Provinsi NTB in 2018. The research was conducted from July to August 2019. The sampling technique in this research was total sampling with 18 samples. The data used is retrospective in 2018. Ceftriaxone and cefotaxime cost-minimization analysis using comparison of the total cost calculation showed that cefotaxime therapy is more cost-minimized Rp 1.297.829 or 26,1% than ceftriaxone therapy. There was a significant difference between hospitalization cost and drug cost for the ceftriaxone and cefotaxime drug groups using the t-Test with p < 0.05.
 Keywords : pneumonia, ceftriaxone, cefotaxime, cost-minimization analysis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
